NVDA
NVIDIA
-- 115.430 TSLA
Tesla
-- 225.310 INTC
Intel
-- 25.920 GOOG
Alphabet-C
-- 162.670 GOOGL
Alphabet-A
-- 160.670 
NEWS
Immuneering Launches Pancreatic Cancer Advisory Board
Thursday, 19th December at 8:00 am
- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer -
- Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and second-line pancreatic cancer for IMM-1-104 -
CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the formation of its Pancreatic Cancer Advisory Board. The advisory board, which comprises world-renowned oncology clinical researchers, will provide strategic medical and clinical guidance to the company as its pipeline, including lead clinical program IMM-1-104, continues to advance.
"We are delighted to welcome such an accomplished group of oncologists with significant clinical research expertise to our newly established pancreatic cancer advisory board," said Ben Zeskind, Ph.D., Co-Founder and CEO of Immuneering. "Each member brings extensive oncology experience and knowledge of the patient journey that will be invaluable as we continue to advance IMM-1-104 further into clinical development. The formation of this board reflects the progress we are making in our efforts to develop better options for pancreatic cancer patients."
Thursday, 19th December at 8:00 am
- Establishment reflects the clinical progress of IMM-1-104 and its promise in pancreatic cancer -
- Follows recent Orphan Drug designation in pancreatic cancer and Fast Track designations in first- and second-line pancreatic cancer for IMM-1-104 -
CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the formation of its Pancreatic Cancer Advisory Board. The advisory board, which comprises world-renowned oncology clinical researchers, will provide strategic medical and clinical guidance to the company as its pipeline, including lead clinical program IMM-1-104, continues to advance.
"We are delighted to welcome such an accomplished group of oncologists with significant clinical research expertise to our newly established pancreatic cancer advisory board," said Ben Zeskind, Ph.D., Co-Founder and CEO of Immuneering. "Each member brings extensive oncology experience and knowledge of the patient journey that will be invaluable as we continue to advance IMM-1-104 further into clinical development. The formation of this board reflects the progress we are making in our efforts to develop better options for pancreatic cancer patients."
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment